journal
Journals Clinical Advances in Hematolog...

Clinical Advances in Hematology & Oncology : H&O

https://read.qxmd.com/read/37647496/selecting-the-optimal-radiation-modality-in-prostate-cancer
#1
REVIEW
Luca F Valle, Amar U Kishan, Antonio Franco, Ting Martin Ma, John Nikitas, Matthew Farrell, Albert J Chang, Nicholas G Nickols, Michael L Steinberg
There are numerous radiation modalities for the definitive treatment of localized prostate cancer. Classic clinical trials have established the basic tenets of treatment approaches, and emerging data have generated new potential avenues of treatment that optimize the therapeutic ratio by increasing prostate cancer tumor control while minimizing treatment-related toxicity. In the definitive setting, the selection of the optimal radiation therapy approach depends largely on the appropriate up-front risk stratification of men with prostate cancer, with greater intensification of treatment and greater integration of multimodality therapies for men with higher-risk disease...
September 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37647495/predicting-outcomes-and-monitoring-disease-in-patients-with-multiple-myeloma
#2
REVIEW
Susanna Kim, James R Berenson
Multiple myeloma (MM) is a clonal plasma cell dyscrasia and the most common form of primary bone marrow cancer. Nearly 35,000 new cases of MM are diagnosed in the United States each year. MM is a slowly progressive illness that remains incurable. The median survival for patients with MM is approximately 7 years, during which these patients suffer substantial morbidity. Despite the introduction of new drugs and immune-based therapies, many patients unfortunately relapse and require further therapies. Therefore, it is becoming increasingly important to be able to accurately and quickly determine changes in a patient's clinical status...
September 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37647494/hem-onc-news
#3
JOURNAL ARTICLE
Devon Schuyler
No abstract text is available yet for this article.
September 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37647493/expanding-the-use-of-parp-inhibitors-in-breast-cancer
#4
Tira Tan
No abstract text is available yet for this article.
September 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37647492/repurposing-drugs-in-oncology
#5
Emile Voest
No abstract text is available yet for this article.
September 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37647491/principles-of-gene-therapy-for-the-hematologist
#6
Janice Staber
No abstract text is available yet for this article.
September 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37530621/management-of-richter-transformation
#7
Matthew S Davids
No abstract text is available yet for this article.
August 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37530620/adjuvant-therapy-in-high-risk-node-negative-melanoma
#8
Merrick I Ross
No abstract text is available yet for this article.
August 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37530619/updates-in-small-cell-lung-cancer
#9
Jacob Sands
No abstract text is available yet for this article.
August 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37530618/more-highlights-in-prostate-cancer-from-the-2023-american-society-of-clinical-oncology-annual-meeting
#10
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
August 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37530617/recent-approval-of-pirtobrutinib-for-mantle-cell-lymphoma
#11
Jonathon B Cohen
No abstract text is available yet for this article.
August 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37530616/novel-sources-of-funding-for-clinical-trials-in-oncology
#12
Gabe S Sonke
No abstract text is available yet for this article.
August 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37530615/neoadjuvant-immunotherapy-in-resectable-non-small-cell-lung-cancer
#13
REVIEW
Sarah E Lochrin, Patrick M Forde
Lung cancer is the leading cause of cancer-related deaths worldwide and is associated with poor 5-year outcomes, even among the 20% to 25% of patients who present with operable disease. Cisplatin-based adjuvant chemotherapy has long been the standard of care for patients with resected non-small cell lung cancer (NSCLC). With the incorporation of immunotherapy, however, the treatment paradigm for NSCLC has changed dramatically. The introduction of immune checkpoint blockade has improved clinical outcomes in multiple phase 2 and 3 trials in both the neoadjuvant and adjuvant setting, resulting in new US Food and Drug Administration approvals in the management of early-stage resectable lung cancer...
August 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37530614/acral-melanoma-clinical-advances-and-hope-for-the-future
#14
REVIEW
Matthew C Perez, Jane L Messina, Lilit Karapetyan, Rogerio I Neves, Vernon K Sondak
Acral melanoma is a rare subtype of melanoma with unique histologic and biologic characteristics. Given its relative rarity compared with nonacral cutaneous melanoma, acral melanoma has been understudied and underrepresented in modern-day prospective clinical trials that have shaped the contemporary management of advanced cutaneous melanoma. Therefore, treatment principles for advanced acral melanoma are mostly derived from retrospective analyses or extrapolated from data largely based on nonacral cutaneous melanoma...
August 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37477997/highlights-from-the-2023-american-society-of-clinical-oncology-annual-meeting-lung-cancer
#15
JOURNAL ARTICLE
Edward S Kim
No abstract text is available yet for this article.
July 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37477996/highlights-from-the-2023-american-society-of-clinical-oncology-annual-meeting-genitourinary-cancer
#16
JOURNAL ARTICLE
Daniel J George
No abstract text is available yet for this article.
July 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37477995/highlights-from-the-2023-american-society-of-clinical-oncology-annual-meeting-gynecologic-cancer
#17
JOURNAL ARTICLE
Robert L Coleman
No abstract text is available yet for this article.
July 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37477994/highlights-from-the-2023-american-society-of-clinical-oncology-annual-meeting-leukemia-and-lymphoma
#18
JOURNAL ARTICLE
Susan O'Brien
No abstract text is available yet for this article.
July 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37477993/highlights-from-the-2023-american-society-of-clinical-oncology-annual-meeting-colorectal-cancer
#19
JOURNAL ARTICLE
Tanios S Bekaii-Saab
No abstract text is available yet for this article.
July 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/37477992/highlights-from-the-2023-american-society-of-clinical-oncology-annual-meeting-breast-cancer
#20
JOURNAL ARTICLE
Hope S Rugo
No abstract text is available yet for this article.
July 2023: Clinical Advances in Hematology & Oncology: H&O
journal
journal
40386
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.